"We are excited to acquire a royalty interest in cliramitug," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "Cliramitug builds on Neurimmune's differentiated scientific approach and promising clinical data to potentially address a significant unmet need in the rapidly growing ATTR-CM market. We believe AstraZeneca is uniquely positioned to leverage its global development and commercial capabilities to maximize cliramitug's potential and bring this important therapy to patients worldwide."
Cliramitug (formerly NI006, ALXN2220) is an investigational human monoclonal antibody discovered by Neurimmune and designed to deplete amyloid deposits from affected hearts in patients with amyloid transthyretin cardiomyopathy (ATTR-CM).1-3 In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca Rare Disease for cliramitug. Alexion is responsible for further clinical development, manufacturing, and commercialization of cliramitug, including the ongoing DepleTTR-CM Phase 3 trial to evaluate the safety and efficacy of cliramitug in adults with ATTR-CM.